Therapeutic combination of 'keys' to target low-density lipoprotein cholesterol level ; Терапевтическая комбинация «ключей» к целевому уровню холестерина липопротеинов низкой плотности

Συγγραφείς: V. V. Kashtalap, D. Yu. Sedykh, В. В. Кашталап, Д. Ю. Седых

Συνεισφορές: Work within the fundamental theme «Development of innovative models for management of cardiovascular disease risk factors and comorbidities based on the study of fundamental, clinical, and epidemiological mechanisms and healthcare management techniques in the industrial region of Siberia (No. 0419-2022-0002)», Работа выполнена в рамках фундаментальной темы НИИ КПССЗ «Разработка инновационных моделей управления риском развития болезней системы кровообращения с учетом коморбидности на основе изучения фундаментальных, клинических, эпидемиологических механизмов и организационных технологий медицинской помощи в условиях промышленного региона Сибири (0419-2022-0002)»

Πηγή: Meditsinskiy sovet = Medical Council; № 5 (2024); 16-21 ; Медицинский Совет; № 5 (2024); 16-21 ; 2658-5790 ; 2079-701X

Θεματικοί όροι: эзетимиб, very high cardiovascular risk, lipid-lowering therapy, statins, ezetimibe, очень высокий сердечно-сосудистый риск, липидснижающая терапия, статины

Περιγραφή αρχείου: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/8217/7240; Мешков АН, Ершова АИ, Деев АИ, Метельская ВА, Жернакова ЮВ, Ротарь ОП и др. Распределение показателей липидного спектра у мужчин и женщин трудоспособного возраста в Российской Федерации: результаты исследования ЭССЕ-РФ за 2012–2014 гг. Кардиоваскулярная терапия и профилактика. 2017;16(4):62–67. https://doi.org/10.15829/1728-8800-2017-4-62-67.; Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459–2472. https://doi.org/10.1093/eurheartj/ehx144.; Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–1278. https://doi.org/10.1016/S0140-6736(05)67394-1.; Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–188. https://doi.org/10.1093/eurheartj/ehz455.; Tokgözoğlu L, Libby P. The dawn of a new era of targeted lipid-lowering therapies. Eur Heart J. 2022;43(34):3198–3208. https://doi.org/10.1093/eurheartj/ehab841.; Оганов РГ, Кухарчук ВВ, Арутюнов ГП, Галявич АС, Гуревич ВС, Дупляков ДВ и др. Сохраняющиеся нарушения показателей липидного спектра у пациентов с дислипидемией, получающих статины, в реальной клинической практике в Российской Федерации (российская часть исследования DYSIS). Кардиоваскулярная терапия и профилактика. 2012;11(4):70–78. https://doi.org/10.15829/1728-8800-2012-4-70-78.; Ray KK, Molemans B, Schoonen WM, Giovas P, Bray S, Kiru G et al. EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. Eur J Prev Cardiol. 2021;28(11):1279–1289. https://doi.org/10.1093/eurjpc/zwaa047.; Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681. https://doi.org/10.1016/S0140-6736(10)61350-5.; Ежов МВ, Сергиенко ИВ, Кухарчук ВВ. Клинические рекомендации по нарушениям липидного обмена 2023. Что нового? Атеросклероз и дислипидемии. 2023;(3):5–9. https://doi.org/10.34687/2219-8202.JAD.2023.03.0001.; Ray KK, Reeskamp LF, Laufs U, Banach M, Mach F, Tokgözoğlu LS et al Combination lipid-lowering therapy as first-line strategy in very high-risk patients. Eur Heart J. 2022;43(8):830–833. https://doi.org/10.1093/eurheartj/ehab718.; Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation. 2003;107(19):2409–2445. https://doi.org/10.1161/01.CIR.0000068312.21969.C8.; Gagné C, Bays HE, Weiss SR, Mata P, Quinto K, Melino M et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol. 2002;90(10):1084–1091. https://doi.org/10.1016/s0002-9149(02)02774-1.; Jia L, Betters JL, Yu L. Niemann-pick C1-like 1 (NPC1L1) protein in intestinal and hepatic cholesterol transport. Annu Rev Physiol. 2011;73:239–259. https://doi.org/10.1146/annurev-physiol-012110-142233.; Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015;372(25):2387–2397. https://doi.org/10.1056/NEJMoa1410489.; Kato ET, Cannon CP, Blazing MA, Bohula E, Guneri S, White JA et al. Efficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). J Am Heart Assoc. 2017;6(11):e006901. https://doi.org/10.1161/JAHA.117.006901.; Шапошник ИИ, Генкель ВВ. Плейотропные эффекты эзетимиба. Кардиология. 2019;59(12S):12–17. https://doi.org/10.18087/cardio.n875.; Gragnano F, Calabrò P. Role of dual lipid-lowering therapy in coronary atherosclerosis regression: Evidence from recent studies. Atherosclerosis. 2018;269:219–228. https://doi.org/10.1016/j.atherosclerosis.2018.01.012.; Toth PP, Morrone D, Weintraub WS, Hanson ME, Lowe RS, Lin J et al. Safety profile of statins alone or combined with ezetimibe: a pooled analysis of 27 studies including over 22,000 patients treated for 6–24 weeks. Int J Clin Pract. 2012;66(8):800–812. https://doi.org/10.1111/j.1742-1241.2012.02964.x.; Iqbal Z, Ho JH, Adam S, France M, Syed A, Neely D et al. Managing hyperlipidaemia in patients with COVID-19 and during its pandemic: An expert panel position statement from HEART UK. Atherosclerosis. 2020;313:126–136. https://doi.org/10.1016/j.atherosclerosis.2020.09.008.; Grewal T, Nguyen MKL, Buechler C. Cholesterol and COVID-19-therapeutic opportunities at the host/virus interface during cell entry. Life Sci Alliance. 2024;7(5):e202302453. https://doi.org/10.26508/lsa.202302453.; Israel A, Schäffer AA, Cicurel A, Feldhamer I, Tal A, Cheng K et al. Identification of drugs associated with reduced severity of COVID-19: A case-control study in a large population. medRxiv. 2021;2020.10.13.20211953. https://doi.org/10.1101/2020.10.13.20211953.; Kim BK, Hong SJ, Lee YJ, Hong SJ, Yun KH, Hong BK et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. Lancet. 2022;400(10349):380–390. https://doi.org/10.1016/S0140-6736(22)00916-3.; Федорова НВ, Седых ДЮ, Кашталап ВВ, Чеснокова ЛЮ, Груздева ОВ, Барбараш ОЛ. Интенсификация липидснижающей терапии у пациентов с острым коронарным синдромом на госпитальном этапе (клиническое наблюдение). Комплексные проблемы сердечно-сосудистых заболеваний. 2019;8(4S):121–129. https://doi.org/10.17802/2306-1278-2019-8-4S-121-129.; Cardoso R, Blumenthal RS, Kopecky S, Lopez-Jimenez F, Martin SS. How Low to Go With Lipid-Lowering Therapies in a Cost-effective and Prudent Manner. Mayo Clin Proc. 2019;94(4):660–669. https://doi.org/10.1016/j.mayocp.2018.08.011.; Rikhi R, Shapiro MD. Newer and Emerging LDL-C Lowering Agents and Implications for ASCVD Residual Risk. J Clin Med. 2022;11(15):4611. https://doi.org/10.3390/jcm11154611.; Барбараш ОЛ, Федорова НВ, Седых ДЮ, Груздева ОВ, Хрячкова ОН, Кашталап ВВ, Филимонова АА. Применение ингибиторов PCSK9 на госпитальном этапе лечения пациентов с острым коронарным синдромом и тяжелыми нарушениями липидного обмена. Российский кардиологический журнал. 2020;25(8):4010. https://doi.org/10.15829/1560-4071-2020-4010.; Седых ДЮ, Кашталап ВВ, Хрячкова ОН, Петрова ТС, Барбараш ОЛ. Интенсификация липидснижающей терапии у пациентов очень высокого риска: возможности комбинации с ингибиторами PCSK9. Российский кардиологический журнал. 2022;27(6):5030. https://doi.org/10.15829/1560-4071-2022-5030.; Lee ZV, Lam H. Aggressive lipid-lowering therapy after percutaneous coronary intervention - for whom and how? AsiaIntervention. 2022;8(1):24–31. https://doi.org/10.4244/AIJ-D-22-00005.; Hammoudeh AJ, Echtay A, Ghanem GY, Haddad J. Achieving low-density lipoprotein cholesterol treatment goals among dyslipidemic individuals in the Levant: the CEntralized Pan-Levant survey on tHE Undertreatment of hypercholeSterolemia (CEPHEUS) study. Curr Med Res Opin. 2014;30(10):1957–1965. https://doi.org/10.1185/03007995.2014.929095.; McCaughey C, Ranganathan D, Kerins M, Murphy G, Murphy R. Dyslipidaemia management in the cardiac rehabilitation clinic of a tertiary referral centre: analysis of the impact of new ESC guidance on LDL-C target achievement. Ir J Med Sci. 2022;191(6):2569–2577. https://doi.org/10.1007/s11845-021-02885-9.

Διαθεσιμότητα: https://www.med-sovet.pro/jour/article/view/8217
https://doi.org/10.21518/ms2024-110

Efficiency of high-intensity therapy with rosuvastatin for secondary prevention of cardiovascular complications in patients with a very high risk ; Эффективность высокоинтенсивной терапии розувастатином для вторичной профилактики сердечно-сосудистых осложнений у пациентов очень высокого риска

Συγγραφείς: T. E. Kolmakova, I. A. Alekseeva, N. A. Tmoyan, M. V. Ezhov, Т. Е. Колмакова, И. А. Алексеева, Н. А. Тмоян, М. В. Ежов

Πηγή: Aterotromboz = Atherothrombosis; № 2 (2021); 56-75 ; Атеротромбоз; № 2 (2021); 56-75 ; 2658-5952 ; 2307-1109 ; 10.21518/2307-1109-2021-2

Θεματικοί όροι: COVID-19, low-density lipoprotein cholesterol (LDL-C), rosuvastatin, very high cardiovascular risk, extreme cardiovascular risk, холестерин липопротеидов низкой плотности (ХС ЛНП), розувастатин, очень высокий сердечно-сосудистый риск, экстремальный сердечно-сосудистый риск

Περιγραφή αρχείου: application/pdf

Relation: https://www.aterotromboz.ru/jour/article/view/256/278; Шаповал И.Н., Никитина С.Ю. (ред.). Здравоохранение в России. Статистический сборник. М.; 2019. 170 с. Режим доступа: https://rosstat.gov.ru/storage/mediabank/Zdravoohran-2019.pdf.; Mach F., Baigent C., Catapano A.L., Koskinas K.C., Casula M., Badimon L. et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–188. https://doi.org/10.1093/eurheartj/ehz455.; Кухарчук В.В., Ежов М.В., Сергиенко И.В., Арабидзе Г.Г., Бубнова М.Г., Балахонова Т.В. и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VII пересмотр. Атеросклероз и дислипидемии. 2020;1(38):7–40. Режим доступа: https://jad.noatero.ru/index.php/jad/article/view/274.; Ference B.A., Ginsberg H.N., Graham I., Ray K.K., Packard C.J., Bruckert E. et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459–2472. https://doi.org/10.1093/eurheartj/ehx144.; Колмакова Т.Е., Алексеева И.А., Ежов М.В. Розувастатин как доступное средство для эффективной профилактики сердечно-сосудистых заболеваний. РМЖ. 2020;10:20–24. Режим доступа: https://www.rmj.ru/articles/kardiologiya/Rozuvastatin_kak_dostupnoe_sredstvo_dlya_effektivnoy_profilaktiki_serdechno-sosudistyh_zabolevaniy/#ixzz6nO976Jge.; Catapano A.L., Graham I., De Backer G., Wiklund O., Chapman M.J., Drexel H. et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. The Task Force for the Management of Dyslipidaemias of the European Society Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2016;37(39):2999–3058. https://doi.org/10.1093/eurheartj/ehw272.; Алексеева И.А., Ежов М.В. Особенности применения фиксированной комбинации розувастатина и эзетимиба для эффективной гиполипидемической терапии. Медицинский совет. 2020;(14):26–32. https://doi.org/10.21518/2079-701X-2020-14-26-32.; Karlson B.W., Wiklund O., Palmer M.K., Nicholls S.J., Lundman P., Barter P.J. Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER. Eur Heart J Cardiovasc Pharmacother. 2016;2(4):212–217. https://doi.org/10.1093/ehjcvp/pvw006.; Baygent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C. et al. Efficacy and safety of cholesterol-lowering treatment:prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–1278. https://doi.org/10.1016/S0140-6736(05)67394-1.; Luvai A., Mbagaya W., Hall A.S., Barth J.H. Rosuvastatin: a review of the pharmacology and clinical effectiveness in cardiovascular disease. Clin Med Insights Cardiol. 2012;6:17–33. https://doi.org/10.4137/CMC.S4324.; Schwartz G.G., Olsson A.G., Ezekowitz M.D., Ganz P., Oliver M.F., Waters D. et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285(13):1711–1718. https://doi.org/10.1001/jama.285.13.1711.; Cannon C.P., Braunwald E., McCabe C.H., Rade D.J., Rouleau J.L., Belder R. et al. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. Pravastatin or Atorvastatin Evaluation and Infection Therapy – Thrombolysis in Myocardial Infarction 22 Investigators. N Engl J Med. 2004;350(15):1495–1504. https://doi.org/10.1056/NEJMoa040583.; Wiviott S.D., Cannon C.P., Morrow D.A., Ray K.K., Pfeffer M.A., Braunwald E. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol. 2005;46(8):1411–1416. https://doi.org/10.1016/j.jacc.2005.04.064.; Boekholdt S.M., Hovingh G.K., Mora S., Arsenault B.J., Amarenco P., Pedersen T.R. et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol. 2014;64(5):485– 494. https://doi.org/10.1016/j.jacc.2014.02.615.; Ray K.K., Cannon C.P., McCabe C.H., Cairns R., Tonkin A.M., Sacks F.M. et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2005;46(8):1405–1410. https://doi.org/10.1016/j.jacc.2005.03.077.; Reiner Ž. Primary Prevention of Cardiovascular Disease with Statins in the Elderly. Curr Atheroscler Rep. 2014;16(7):420. https://doi.org/10.1007/s11883-014-0420-6.; McKenney J.M., Jones P.H., Adamczyk M.A., Cain V.A., Bryzinski B.S., Blasetto J.W. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin. 2003;19(8):689–698. https://doi.org/10.1185/030079903125002405.; Sexton T.R., Wallace E.L., Macaulay T.E., Charnigo R.J., Evangelista V., Campbell C.L. et al. The effect of rosuvastatin on thromboinflammation in the setting of acute coronary syndrome. J Thromb Thrombolysis. 2015;39(2):186–195. https://doi.org/10.1007/s11239-014-1142-x.; Maroo B.P., Lavie C.J., Milani R.V. Secondary prevention of coronary heart disease in elderly patients following myocardial infarction: are all HMG-CoA reductase inhibitors alike? Drugs Aging. 2008;25(8):649–664. https://doi.org/10.2165/00002512-200825080-00003.; Hall A.S., Jackson B.M., Farrin A.J., Efthymiou M., Barth J.H., Copeland J. et al. A randomized, controlled trial of simvastatin versus rosuvastatin in patients with acute myocardial infarction: the Secondary Prevention of Acute Coronary Events – Reduction of Cholesterol to Key European Targets Trial. Eur J Cardiovasc Prev Rehabil. 2009;16(6):712–721. https://doi.org/10.1097/HJR.0b013e3283316ce8.; Lablanche J.M., Danchin N., Farnier M., Tedgui A., Vicaut E., Alonso J. et al. Effects of rosuvastatin and atorvastatin on the apolipoprotein B/apolipoprotein A-1 ratio in patients with an acute coronary syndrome: The CENTAURUS trial design. Arch Cardiovasc Dis. 2008;101(6):399–406. Available at: https://pubmed.ncbi.nlm.nih.gov/18809153.; Yun K.H., Jeong M.H., Oh S.K., Rhee S.J., Park E.M., Lee E.M. et al. The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome. Int J Cardiol. 2009;137:246–251. Available at: https://pubmed.ncbi.nlm.nih.gov/18706705.; Cay S., Cagirci G., Sen N., Balbay Y., Durmaz T., Aydogdu S. Prevention of Peri-procedural Myocardial Injury using a Single High Loading Dose of Rosuvastatin. Cardiovasc Drugs Ther. 2010;24(1):41–47. https://doi.org/10.1007/s10557-010-6224-1.; Ye Z., Lu H., Su Q., Guo W., Dai W., Li H. et al. Effect of high-dose rosuvastatin loading before percutaneous coronary intervention in Chinese patients with acute coronary syndrome: A systematic review and meta-analysis. PLoS ONE. 2017;12(2):e0171682. https://doi.org/10.1371/journal.pone.0171682.; Guo J., Zhang W.Z., Zhao Q., Wo J.S., Cai S.L. Study on the effect of different doses of rosuvastatin on ventricular remodeling in patients with acute coronary syndrome after emergency percutaneous coronary intervention. Eur Rev Med Pharmacol Sci. 2017;21(19):4457–4463. https://pubmed.ncbi.nlm.nih.gov/29077146.; Toso A., Leoncini M., Maioli M., Tropeano F., Di Vincenzo E. , Villani S., Bellandi F. Relationship between inflammation and benefits of early high-dose rosuvastatin on contrast-induced nephropathy in patients with acute coronary syndrome: the pathophysiological link in the PRATO-ACS study (Protective Effect of Rosuvastatin and Antiplatelet Therapy on Contrast-Induced Nephropathy and Myocardial Damage in Patients With Acute Coronary Syndrome Undergoing Coronary Intervention). JACC Cardiovasc Interv. 2014;7(12):1421–1429. Available at: https://pubmed.ncbi.nlm.nih.gov/25523533.; Almeida S.O., Budoff M. Effect of statins on atherosclerotic plaque. Trends Cardiovasc Med. 2019;29(8):451–455. Available at: https://pubmed.ncbi.nlm.nih.gov/30642643.; Nicholls S.J., Ballantyne C.M., Barter P.J., Chapman M.J., Erbel R.M., Libby P. et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365(22):2078–2087. https://doi.org/10.1056/NEJMoa1110874.; Nissen S.E., Tuzcu E.M., Schoenhagen P., Brown B.G., Ganz P., Vogel R.A. et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291(9):1071–1080. https://doi.org/10.1001/jama.291.9.1071.; Kini A.S., Baber U., Kovacic J.C., Limaye A., Ali Z.A., Sweeny J. et al. Changes in Lipid Content After Short – Term Intensive Versus Standart StatinTherapy/ The YELLOW Trial (reductioninYellow Plaque by Aggressive Li pid-Lowering Therapy). J Am Coll Cardiol. 2013;62(1):21–29. https://doi.org/10.1016/j.jacc.2013.03.058.; Hong Y.J., Jeong M.H., Hachinohe D., Ahmed K., Choi Y.H., Cho S.H. et al. Comparison of effects of rosuvastatin and atorvastatin on plaque regression in Korean patients with untreated intermediate coronary stenosis. Circ J. 2011;75(2):398–406. https://doi.org/10.1253/circj.cj-10-0658.; Haddad R.M., Ballantyne C.M. METEOR Trial Reports on the Effect of Rosuvastatin on Progression of Carotid IntimaMedia Thickness in Low-Risk Individuals with Subclinical Atherosclerosis. Phys Sportsmed. 2010;38(2):180–182. https://doi.org/10.3810/psm.2010.06.1797.; Underhill H.R., Yuan C., Zhao X.Q., Kraiss L.W., Parker D.L., Saam T. et al. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonanceimaging trial. Am Heart J. 2008;155(3):584.e1–8. https://doi.org/10.1016/j.ahj.2007.11.018.; Kjekshus J., Apetrei E., Barrios V., Böhm M., Cleland J.G., Cornel J.H. et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357(22):2248–2261. https://doi.org/10.1056/NEJMoa0706201.; Tavazzi L., Maggioni A.P., Marchioli R., Barlera S., Franzosi M.G., Latini R. et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9645):1231–1239. Available at: https://pubmed.ncbi.nlm.nih.gov/18757089.; Fellström B.C., Jardine A.G., Schmieder R.E., Holdaas H., Bannister K., Beutler J. et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395–1407. https://doi.org/10.1056/NEJMoa0810177.; Авдеев С.Н., Адамян Л.В., Алексеева Е.И., Багненко С.Ф., Баранов А.А., Баранова Н.Н. и др. Временные методические рекомендации Минздрава России. Профилактика. диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 10 (08.02.2021). М.; 2021. 262 с. Режим доступа: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/054/662/original/%D0%92%D1%80%D0%B5%D0%BC%D0%B5%D0%BD%D0%BD%D1%8B%D0%B5_%D0%9C%D0%A0_COVID-19_%28v.10%29.pdf.; Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Bethesda (MD): National Institutes of Health (US); 2021. Available at: https://pubmed.ncbi.nlm.nih.gov/34003615.; Bifulco M., Gazzerro P. Statins in coronavirus outbreak: it’s time for experimental and clinical studies. Pharmacol Res. 2020;156:104803. https://doi.org/10.1016/j.phrs.2020.104803.; Gupta A., Madhavan M.V., Sehgal K., Nair N., Mahajan S., Sehrawat T.S. et al. Extrapulmonary manifestations of COVID19. Nat Med. 2020;26(7):1017–1032. https://doi.org/10.1038/s41591-020-0968-3.; Zhang X.J., Qin J.J., Cheng X., Shen L., Zhao Y.C., Yuan Y. et al. In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19. Cell Metab. 2020;32(2):176–187.e4. https://doi.org/10.1016/j.cmet.2020.06.015.; Daniels L.B., Sitapati A.M., Zhang J., Zou J., Bui Q.M., Ren J. et al. Relation of Statin Use Prior to Admission to Severity and Recovery Among COVID-19 Inpatients. Am J Cardiol. 2020;136:149–155. https://doi.org/10.1016/j.amjcard.2020.09.012.; Kow C.S., Hasan S.S. Meta-analysis of Effect of Statins in Patients with COVID-19. Am J Cardiol. 2020;134:153–155. https://doi.org/10.1016/j.amjcard.2020.08.004.; Hariyanto T.I., Kurniawan A. Statin therapy did not improve the in-hospital outcome of coronavirus disease 2019 (COVID-19) infection. Diabetes Metab Syndr. 2020;14(6):1613–1615. https://doi.org/10.1016/j.dsx.2020.08.023.; Iqbal Z., Ho J.H., Adam S., France M., Syed A., Neely D. et al. Managing hyperlipidaemia in patients with COVID-19 and during its pandemic: An expert panel position statement from HEART UK. Atherosclerosis. 2020;313:126–136. https://doi.org/10.1016/j.atherosclerosis.2020.09.008.; Шальнова С.А., Деев А.Д., Метельская В.А., Евстифеева С.Е., Ротарь О.П., Жернакова Ю.В. и др. Информированность и особенности терапии статинами у лиц с различным сердечно-сосудистым риском: исследование ЭССЕ-РФ. Кардиоваскулярная терапия и профилактика. 2016;(4):29–37. https://doi.org/10.15829/1728-8800-2016-4-29-37.; Бойцов С.А., Якушин С.С., Марцевич С.Ю., Лукьянов М.М., Никулина Н.Н., Загребельный А.В. и др. Амбулаторно-поликлинический регистр кардиоваскулярных заболеваний в Рязанской области (РЕКВАЗА): основные задачи, опыт создания и первые результаты. Рациональная фармакотерапия в кардиологии. 2013;(1):4–14. https://doi.org/10.20996/1819-6446-2013-9-1-4-14.; https://www.aterotromboz.ru/jour/article/view/256

Διαθεσιμότητα: https://www.aterotromboz.ru/jour/article/view/256
https://doi.org/10.21518/2307-1109-2021-11-2-56-75

Новый вектор снижения сердечно-сосудистого риска – интенсивная гиполипидемическая терапия

Θεματικοί όροι: low-density lipoprotein cholesterol, treatment compliance, статины, fixed combination of rosuvastatin and ezetimibe, холестерин липопротеидов низкой плотности, high and very high cardiovascular risk, высокий и очень высокий сердечно-сосудистый риск, 3. Good health, фиксированная комбинация розувастатина и эзетимиба, приверженность терапии, statins